| Waylivra (volanesorsen) / Novartis, SOBI |
NCT05185843 / 2021-003635-29: A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adults With Familial Chylomicronemia Syndrome (FCS) Previously Treated With Volanesorsen |
|
|
| Active, not recruiting | 3 | 24 | Europe, Canada, US | Olezarsen, ISIS 678354, AKCEA-APOCIII-LRx | Ionis Pharmaceuticals, Inc. | Familial Chylomicronemia Syndrome | 03/25 | 06/25 | | |
NCT03544060: Volanesorsen Early Access Program for Patients With Familial Chylomicronemia Syndrome (FCS) |
|
|
| No Longer Available | N/A | | NA | Volanesorsen, Waylivra | Akcea Therapeutics, CaligorRx, Inc. | Familial Chylomicronemia | | | | |
| olezarsen (Ionis-APOCIII-LRx) / Ionis |
2021-003280-95: An Open-Label Extension Study of AKCEA-APOCIII-LRX Administered to Patients with Familial Chylomicronemia Syndrome (FCS) Estudio abierto de prolongación de AKCEA-APOCIII-LRx administrado a pacientes con síndrome de quilomicronemia familiar (SQF) |
|
|
| Not yet recruiting | 3 | 60 | Europe | ISIS 678354, ISIS 678354, Solution for injection | Ionis Pharmaceuticals, Inc., IONIS PHARMACEUTICALS, INC., Ionis | Familial Chylomicronemia Syndrome (FCS) Síndrome de quilomicronemia familiar (SQF), Patients with hypertriglyceridemia Pacientes con hipertrigliceridemia, Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | | | | |
BALANCE, NCT04568434: A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) Administered to Patients With Familial Chylomicronemia Syndrome (FCS) |
|
|
| Completed | 3 | 66 | Europe, Canada, US, RoW | Olezarsen, ISIS 678354, AKCEA-APOCIII-LRx, Placebo | Ionis Pharmaceuticals, Inc., Akcea Therapeutics | Familial Chylomicronemia Syndrome | 07/23 | 10/23 | | |
2020-002536-67: A Study of AKCEA-APOCIIILRx Administered to Patients With Familial Chylomicronemia Syndrome (FCS) |
|
|
| Not yet recruiting | 3 | 60 | Europe | ISIS 678354, ISIS 678354, Solution for injection | Ionis Pharmaceuticals, Inc., IONIS PHARMACEUTICALS, INC., Ionis | Familial Chylomicronemia Syndrome (FCS), Patients with hypertriglyceridemia, Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | | | | |
| Active, not recruiting | 3 | 617 | Europe, Canada, US, RoW | Olezarsen, AKCEA-APOCIII-LRx, ISIS 678354, Placebo | Ionis Pharmaceuticals, Inc. | Severe Hypertriglyceridemia | 04/25 | 07/25 | | |
NCT05130450: A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS) |
|
|
| Active, not recruiting | 3 | 60 | Europe, Canada, US | Olezarsen, ISIS 678354, AKCEA -APOCIII-LRx | Ionis Pharmaceuticals, Inc. | Familial Chylomicronemia Syndrome | 01/25 | 04/25 | | |
NCT05610280: A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia |
|
|
| Active, not recruiting | 3 | 1478 | Europe, Canada, US, RoW | Olezarsen, ISIS 678354, AKCEA-APOCIII-LRx, Placebo | Ionis Pharmaceuticals, Inc. | Hypertriglyceridemia, Cardiovascular Diseases, Atherosclerosis | 03/25 | 06/25 | | |
NCT05552326: A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia |
|
|
| Active, not recruiting | 3 | 446 | Europe, Canada, US, RoW | Olezarsen, ISIS 678354, AKCEA-APOCIII-LRx, Placebo | Ionis Pharmaceuticals, Inc. | Severe Hypertriglyceridemia | 06/25 | 07/25 | | |
NCT05681351: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG) |
|
|
| Recruiting | 3 | 700 | Europe, Canada, US, RoW | Olezarsen, AKCEA-APOCIII-LRx, ISIS 678354 | Ionis Pharmaceuticals, Inc. | Severe Hypertriglyceridemia | 05/26 | 09/26 | | |
NCT05355402: A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia |
|
|
| Completed | 2 | 154 | Canada, US | Olezarsen, ISIS 678354, AKCEA-APOCIII-LRx, Placebo | Ionis Pharmaceuticals, Inc. | Hypertriglyceridemia, Atherosclerotic Cardiovascular Disease, Severe Hypertriglyceridemia | 03/23 | 12/23 | | |
NCT05579860: A Study Comparing Two Subcutaneous Formulations: Vial and Autoinjector (AI) With Olezarsen, at Two Dose Levels, in Healthy Adult Participants |
|
|
| Completed | 1 | 104 | US | Olezarsen, ISIS 678354 | Ionis Pharmaceuticals, Inc. | Healthy Participants | 05/23 | 05/23 | | |
NCT06360237: Olezarsen Early Access Program for Patients With Familial Chylomicronemia Syndrome (FCS) |
|
|
| Available | N/A | | US | Olezarsen, ISIS-678354 | Ionis Pharmaceuticals, Inc. | Familial Chylomicronemia Syndrome | | | | |
| plozasiran (ARO-APOC3) / Arrowhead |
| Active, not recruiting | 3 | 75 | Europe, Canada, Japan, US, RoW | Plozasiran, ARO-APOC3, Placebo | Arrowhead Pharmaceuticals | Familial Chylomicronemia | 04/24 | 04/26 | | |
| Recruiting | 3 | 1328 | Canada, US | Plozasiran Injection, ARO-APOC3, Placebo | Arrowhead Pharmaceuticals | Hypertriglyceridemia | 07/26 | 10/26 | | |
| Recruiting | 3 | 405 | Canada, US | Plozasiran Injection, ARO-APOC3, Placebo | Arrowhead Pharmaceuticals | Severe Hypertriglyceridemia | 07/26 | 10/26 | | |
| Recruiting | 3 | 300 | Canada, US | Plozasiran Injection, ARO-APOC3, Placebo | Arrowhead Pharmaceuticals | Severe Hypertriglyceridemia | 07/26 | 10/26 | | |
NCT05902598: A Phase 3 Study of VSA001 in Chinese Adults With Familial Chylomicronemia Syndrome |
|
|
| Not yet recruiting | 3 | 30 | NA | VSA001 injection, ARO-APOC3, Placebo, Normal saline | Visirna Therapeutics HK Limited | Familial Chylomicronemia Syndrome | 12/24 | 12/25 | | |
ChiCTR2400090216: Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults with Severe Hypertriglyceridemia (SHASTA-3 Study) |
|
|
| Not yet recruiting | 3 | 405 | | Plozasiran 25mg; Placebo | Peking University First Hospital; Peking University First Hospital, Arrowhead Pharmaceuticals, Inc. | Severe Hypertriglyceridemia | | | | |
2022-001135-85: A Long-Term Study to Evaluate ARO-APOC3 in Adults with Dyslipidemia |
|
|
| Not yet recruiting | 2 | 582 | Europe | ARO-APOC3 Injection, ARO-APOC3, Solution for injection | Arrowhead Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Inc. | Mixed Dyslipidemia, high LDL cholesterol and triglyceride levels, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
| Completed | 2 | 353 | Europe, Canada, US, RoW | ARO-APOC3, Placebo | Arrowhead Pharmaceuticals | Mixed Dyslipidemia | 02/23 | 08/23 | | |
| Completed | 2 | 229 | Europe, Canada, US, RoW | ARO-APOC3, Placebo | Arrowhead Pharmaceuticals | Severe Hypertriglyceridemia | 03/23 | 08/23 | | |
2021-000687-30: A study to understand the safety and effectivness of ARO-APOC3 in Adults with Severe Hypertriglyceridemia |
|
|
| Not yet recruiting | 2 | 300 | Europe | ARO-APOC3 Injection, ARO-APOC3, Solution for injection | Arrowhead Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Inc. | Severe Hypertriglyceridemia, abnormal triglyceride levels, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
| Active, not recruiting | 2 | 418 | Europe, Canada, US, RoW | ARO-APOC3 | Arrowhead Pharmaceuticals | Dyslipidemias | 10/25 | 10/25 | | |
NCT05757596: Study of VSA001 Injection in Chinese Healthy Adult Volunteers |
|
|
| Not yet recruiting | 1 | 24 | RoW | VSA001 injection, Placebo | Visirna Therapeutics HK Limited, Arrowhead Pharmaceuticals | Healthy Adult Volunteers | 12/23 | 12/23 | | |
| RBD5044 / Suzhou Ribo |
NCT05539651: A Single and Multiple Ascending Doses Study to Evaluate the Safety and Pharmacokinetics of RBD5044 |
|
|
| Recruiting | 1 | 72 | RoW | RBD5044, Placebo | Suzhou Ribo Life Science Co. Ltd. | Health Volunteer | 08/24 | 10/24 | | |
| LY3875383 / Eli Lilly |
NCT05609825: A Study of LY3875383 in Healthy Participants and Participants With Hypertriglyceridemia |
|
|
| Completed | 1 | 41 | RoW | LY3875383, Placebo | Eli Lilly and Company | Hypertriglyceridemia | 01/24 | 01/24 | | |
